Polymorphisms in vascular endothelial growth factor receptor 2 are associated 
with better response rates to ranibizumab treatment in age-related macular 
degeneration

Hermann, Manuel M.; van Asten, Freekje; Muether, Philipp S.; Smailhodzic, Dzenita; Lichtner, Peter; Hoyng, Carel B.; Kirchhof, Bernd; Grefkes, Christian; den Hollander, Anneke I.; Fauser, Sascha

doi:10.1016/j.ophtha.2013.10.047

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration

MPS-Authors

/persons/resource/persons147178

Grefkes, Christian
Neuromodulation und Neurorehabilitation, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Hermann, M. M., van Asten, F., Muether, P. S., Smailhodzic, D., Lichtner, P., Hoyng, C. B., Kirchhof, B., Grefkes, C., den Hollander, A. I., & Fauser, S. (2014). Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration. Ophthalmology, 121(4), 905-910. doi:10.1016/j.ophtha.2013.10.047.

引用: https://hdl.handle.net/11858/00-001M-0000-0026-D836-D